Detailed Quote
Price History
SEC Filings
News & Events
Governance
Leadership
Haohan Xu
CEO
Haohan Xu is a technology-focused entrepreneur who has been CEO and Chairperson at Fresh2 Group Limited since October 2022. He founded Apifiny, a regulated digital asset trading platform, in 2018 and Roxe, a global payment network, in 2019. . He studied operations research and computer science at Columbia University.
Xiaoyu Li
CFO
Xiaoyu Li has extensive experience in investor relations management, investment and M&A. Ms. Li served as director of MFH (nasdaq listed) between May 2018 and August 2021. She served at investor relations department from 2012 to 2013 for WOWO, which is a Nasdaq listed company. She helped and supported the whole process of IPO of the company, including IPO preparation, IPO process and post-IPO communication with investors. Ms. Li holds a master’s degree in finance from University of Illinois at Urbana-Champaign, and a bachelor’s degree in economics from University of Minnesota.
Honggang Tian
Board of Director
Mr. Tian is an experienced investment professional, with particular focus in Internet and high-tech industries. From 09/2017 to 09/2022, Harvey served as a Partner of PAUVEY Capital Ltd. He holds a master’s degree in engineering Wuhan University and a bachelor’s degree in engineering from Wuhan University.
Tianruo Pu
Board of Director
Mr. Pu currently serves as an independent director of Autohome Inc. (NYSE: ATHM; HKSE: 2518), One Connect Financial Technology (NYSE: OCFT) and 3SBio Inc. (HKSE: 1530). Mr. Pu holds a MBA in finance Northwestern University Kellogg School of Management, a master’s degree in accounting from University of Illinois at, and a bachelor’s degree in English Language from China Foreign Affairs University.
Zhigang Zhao
Board of Director
Mr. Frank Zhigang Zhao CPA，has over two decades of experience in financial and accounting management with auditing firms and public companies. Served as Chief Executive Officer of Uni-bioscience since 2019. Priorly，served as the Chief Financial Officer of Wowo Limited from June 2014 to 2019; chief financial officer of Borqs International Limited from 2012 to 2014. Mr. Zhao was the chief financial officer of Simcere Pharmaceutical Group from 2006 to 2011. From 2005 to 2006 Mr. Zhao worked as the chief financial officer of Sun New Media Inc. From 2003 to 2005 Mr. Zhao worked at FARO Technologies Inc. as a financial controller. Mr. Zhao received his bachelor degree in economics from Peking University and MBA degree from University of Hartford. Mr. Zhao is a US certified public accountant since 1993.
Zhijun Liang
Board of Director
Zhijun Liang has spent more than two decades providing management consulting and investment management services, primarily to start-ups and growth businesses, enabling them to address expansion needs and financial challenges. Since 2008, Mr. Liang has been the co- founder of Shanghai Bajun Investment Management, overseeing its business development and participating in its portfolio management. He is also a founding member of Beijing Yuantong Funds Management Co., Ltd., leading its risk management unit. Concurrently, he served as the Director of Investment for Daohe Global from 2016-2017. As the Managing Partner of Shanghai Tongdai Business Management Consulting LLP since 2017, he manages the firm’s financial and management advisory services, dedicated to delivering premium solutions tailored to the unique needs of its clients. Mr. Liang holds an MBA degree in general management from HEC Montreal, the business school of the University of Montreal and a Bachelor of Arts degree in English Language and Literature from South-Central University for Nationalities.
Section IV. Current Directors and Executive Officers
Board of Directors
Audit Committee
Nomination Committee
Compensation Committee
Haohan Xu
Chairperson
Xiaoyu Li
Director
Zhijun Liang
Board of Director
Tianruo Pu
Independent Director
Chairperson
Member
Member
Honggang Tian
Independent Director
Member
Chairperson
Member
Zhigang Zhao
Independent Director
Member
Member
Chairperson
AnPac Bio-Medical Science Co., Ltd. – December 31, 2022
Total Number of Directors
5
Part I: Gender Identity
Female
Male
Non-Binary
Did Not Disclose Gender
Directors
1
4
Part II: Demographic Background
African American or Black
Alaskan Native or American Indian
Asian
5
Hispanic or Latinx
Native Hawaiian or Pacific Islander
White
Two or More Races or Ethnicities
LGBTQ+
Did Not Disclose Demographic Background
Fresh2 Group Limited – December 31, 2023
Total Number of Directors
5
Part I: Gender Identity
Female
Male
Non-Binary
Did Not Disclose Gender
Directors
1
4
Part II: Demographic Background
African American or Black
Alaskan Native or American Indian
Asian
5
Hispanic or Latinx
Native Hawaiian or Pacific Islander
White
Two or More Races or Ethnicities
LGBTQ+
Did Not Disclose Demographic Background
Fresh2 Group Limited – January 16, 2024
Total Number of Directors
6
Part I: Gender Identity
Female
Male
Non-Binary
Did Not Disclose Gender
Directors
1
5
Part II: Demographic Background
African American or Black
Alaskan Native or American Indian
Asian
6
Hispanic or Latinx
Native Hawaiian or Pacific Islander
White
Two or More Races or Ethnicities
LGBTQ+
Did Not Disclose Demographic Background
Documents
Corporate Governance Overview
The Board of Directors of AnPac Bio (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these charters and guidelines. These charters and guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
